DMT1 (NRAMP2/DCT1) Genetic Variability and Resistance to Recombinant Human Erythropoietin Therapy in Chronic Kidney Disease Patients under Haemodialysis

Acta Haematologica

Volumn 120, Issue 1, 2008, Pages 11-13

  Costa, Elísio ^a,b,c   Rocha, Susana ^a,b   Rocha Pereira, Petronila ^b,d   Reis, Flávio ^e   Castro, Elisabeth ^a,b   Teixeira, Frederico ^e   Miranda, Vasco ^f   Do Sameiro Faria, Maria ^f   Loureiro, Alfredo ^g   Quintanilha, Alexandre ^a,b   Belo, Luís ^a,b   Santos Silva, Alice ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

^f FMC   (Australia)

^g Uninefro Sociedade Prestadora de Cuidados Médicos e de Diálise   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALLELE; ARTICLE; BIOSYNTHESIS; CHRONIC KIDNEY DISEASE; DNA POLYMORPHISM; ERYTHROPOIESIS; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMODIALYSIS; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; POPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SAMPLE SIZE;

EID: 48049113949     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149496     Document Type: Article

References (10)

1. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001;38:1408-1413.
2. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-2379.
3. Deicher R, Horl WH: New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006;36:301-309.
4. Costa E, Pereira BJG, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, Sameiro-Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008;28:677-683.
5. Wallace DF, Subramaniam VN: Non-HFE haemochromatosis. World J Gastroenterol 2007;13: 4690-4698.
6. Valenti L, Valenti G, Como G, Santorelli G, Dongiovanni P, Rametta R, Fracanzani AL, Tavazzi D, Messa PG, Fargion S: HFE genotype influences erythropoiesis support requirement in hemodialysis patients: a prospective study. Am J Nephrol 2008;28:311-316.
7. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC: Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997;16:383-386.
8. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S, European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
9. Kelleher T, Ryan E, Barrett S, O'Keane C, Crowe J: DMT1 genetic variability is not responsible for phenotype variability in hereditary HFE. Blood Cells Mol Dis 2004;33:35-39.
10. Excoffier L, Laval LG, Schneider S: Arlequin ver 3.0: an integral software package for population genetics data analysis. Evol Bioinformatics Online 2005;1:47-50.